Skip to main content
All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for AMGEN · Biotechnology.

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Government bodies contacted 6
  • Centers For Medicare and Medicaid Services (CMS)
  • Executive Office of the President (EOP)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • S 3788
    CLEAR LABELS Act
 Lobbying activity 4
Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. Issues related to the Most Favored Nation drug pricing.

Health Issues

Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act.

Copyright/Patent/Trademark

Monitored issues related to intellectual property.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem